ADC Therapeutics (ADCT) Competitors

ADC Therapeutics logo
$1.36 +0.11 (+8.40%)
Closing price 03:59 PM Eastern
Extended Trading
$1.34 -0.02 (-1.48%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ADCT vs. ANNX, RIGL, IRWD, VSTM, and AURA

Should you buy ADC Therapeutics stock or one of its competitors? ADC Therapeutics's main competitors and comparable companies include Annexon (ANNX), Rigel Pharmaceuticals (RIGL), Ironwood Pharmaceuticals (IRWD), Verastem (VSTM), and Aura Biosciences (AURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ADC Therapeutics compare to Annexon?

Annexon (NASDAQ:ANNX) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Annexon has a net margin of 0.00% compared to ADC Therapeutics' net margin of -95.73%. ADC Therapeutics' return on equity of 0.00% beat Annexon's return on equity.

Company Net Margins Return on Equity Return on Assets
AnnexonN/A -106.82% -76.75%
ADC Therapeutics -95.73%N/A -28.26%

Annexon presently has a consensus price target of $15.29, suggesting a potential upside of 340.51%. ADC Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 269.00%. Given Annexon's stronger consensus rating and higher possible upside, equities analysts clearly believe Annexon is more favorable than ADC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annexon
2 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

ADC Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnnexonN/AN/A-$206.69M-$1.04N/A
ADC Therapeutics$81.36M2.34-$142.62M-$0.52N/A

41.1% of ADC Therapeutics shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annexon has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market.

In the previous week, Annexon had 14 more articles in the media than ADC Therapeutics. MarketBeat recorded 15 mentions for Annexon and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.53 beat Annexon's score of 0.10 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annexon
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ADC Therapeutics beats Annexon on 8 of the 14 factors compared between the two stocks.

How does ADC Therapeutics compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rigel Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$294.28M2.75$367.02M$15.512.77
ADC Therapeutics$81.36M2.34-$142.62M-$0.52N/A

In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Rigel Pharmaceuticals and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.53 beat Rigel Pharmaceuticals' score of 0.10 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rigel Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rigel Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

Rigel Pharmaceuticals presently has a consensus price target of $66.75, suggesting a potential upside of 55.52%. ADC Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 269.00%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Rigel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Rigel Pharmaceuticals has a net margin of 106.59% compared to ADC Therapeutics' net margin of -95.73%. Rigel Pharmaceuticals' return on equity of 14.89% beat ADC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals106.59% 14.89% 11.99%
ADC Therapeutics -95.73%N/A -28.26%

Summary

Rigel Pharmaceuticals beats ADC Therapeutics on 11 of the 14 factors compared between the two stocks.

How does ADC Therapeutics compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

41.1% of ADC Therapeutics shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for Ironwood Pharmaceuticals and 1 mentions for ADC Therapeutics. Ironwood Pharmaceuticals' average media sentiment score of 0.79 beat ADC Therapeutics' score of 0.53 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ironwood Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$296.15M2.72$24.02M$0.905.41
ADC Therapeutics$81.36M2.34-$142.62M-$0.52N/A

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, suggesting a potential upside of 27.99%. ADC Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 269.00%. Given ADC Therapeutics' higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Ironwood Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 37.38% compared to ADC Therapeutics' net margin of -95.73%. ADC Therapeutics' return on equity of 0.00% beat Ironwood Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals37.38% -81.40% 42.69%
ADC Therapeutics -95.73%N/A -28.26%

Summary

Ironwood Pharmaceuticals beats ADC Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Verastem?

ADC Therapeutics (NYSE:ADCT) and Verastem (NASDAQ:VSTM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

ADC Therapeutics has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$81.36M2.34-$142.62M-$0.52N/A
Verastem$30.91M30.21-$209.47M-$2.05N/A

ADC Therapeutics has a net margin of -95.73% compared to Verastem's net margin of -178.38%. ADC Therapeutics' return on equity of 0.00% beat Verastem's return on equity.

Company Net Margins Return on Equity Return on Assets
ADC Therapeutics-95.73% N/A -28.26%
Verastem -178.38%-359.49%-78.60%

ADC Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, Verastem has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

ADC Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 269.00%. Verastem has a consensus price target of $16.83, indicating a potential upside of 127.17%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Verastem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Verastem
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 5.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Verastem had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Verastem and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.53 beat Verastem's score of 0.01 indicating that ADC Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Verastem
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

ADC Therapeutics beats Verastem on 10 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to Aura Biosciences?

ADC Therapeutics (NYSE:ADCT) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by insiders. Comparatively, 1.9% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aura Biosciences has a net margin of 0.00% compared to ADC Therapeutics' net margin of -95.73%. ADC Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ADC Therapeutics-95.73% N/A -28.26%
Aura Biosciences N/A -64.68%-56.08%

Aura Biosciences has lower revenue, but higher earnings than ADC Therapeutics. Aura Biosciences is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$81.36M2.34-$142.62M-$0.52N/A
Aura BiosciencesN/AN/A-$106.19M-$1.64N/A

In the previous week, Aura Biosciences had 17 more articles in the media than ADC Therapeutics. MarketBeat recorded 18 mentions for Aura Biosciences and 1 mentions for ADC Therapeutics. Aura Biosciences' average media sentiment score of 0.64 beat ADC Therapeutics' score of 0.53 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aura Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

ADC Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

ADC Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 269.00%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 144.76%. Given ADC Therapeutics' higher possible upside, equities analysts clearly believe ADC Therapeutics is more favorable than Aura Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

ADC Therapeutics beats Aura Biosciences on 7 of the 13 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADCT vs. The Competition

MetricADC TherapeuticsBiotechnology IndustryHealthcare SectorNYSE Exchange
Market Cap$175.83M$4.06B$7.82B$23.17B
Dividend YieldN/A3.63%2.47%3.82%
P/E RatioN/A25.6832.7624.41
Price / Sales2.3416.068.563.22
Price / CashN/A22.9521.0115.54
Price / Book-0.774.184.463.65
Net Income-$142.62M-$24.15M$3.52B$1.07B
7 Day Performance-9.97%-7.25%-5.47%-3.74%
1 Month Performance-3.56%-5.98%-4.57%-2.47%
1 Year Performance-65.83%-7.72%-1.79%6.03%

ADC Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADCT
ADC Therapeutics
1.9043 of 5 stars
$1.36
+8.4%
$5.00
+269.0%
-68.0%$175.83M$81.36MN/A191
ANNX
Annexon
3.3446 of 5 stars
$4.20
-0.8%
$15.29
+264.4%
+31.7%$795.29MN/AN/A92
RIGL
Rigel Pharmaceuticals
4.2789 of 5 stars
$42.77
+1.7%
$66.75
+56.1%
+4.3%$791.25M$294.28M2.76174
IRWD
Ironwood Pharmaceuticals
3.0491 of 5 stars
$4.79
+2.2%
$6.23
+30.3%
+54.5%$790.67M$400.30M5.32100
VSTM
Verastem
2.7063 of 5 stars
$8.66
-0.4%
$16.83
+94.3%
+2.0%$784.61M$30.91MN/A102

Related Companies and Tools


This page (NYSE:ADCT) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners